Inflammatory Bowel Disease (IBD) Models

Validated IBD Models

Chemically Induced Models

Dextran Sulfate Sodium (DSS) induced model
TNBS induced model
Oxazolone induced model
Indomethacin-induced colitis

Genetically Engineered Models

IL-10 knockout colitis model
Mdr1a knockout
SAMP1/Fc mouse

Immune-Mediated Models

End-to-End IBD Research Services

Model Establishment

Validated induction protocols with high reproducibility

Customized Study Design

Strategies tailored to small molecules, biologics, and immunotherapies

Efficacy Evaluation

Clinical scoring (DAI score) and disease activity assessment

Mechanistic Analysis

Immune, molecular, and pharmacodynamic profiling

Chronic & Translational Studies

Long-term monitoring aligned with clinical relevance

Integrated Readouts

Histology, immune cell profiling, cytokine profiling, gene and protein expression analysis and optional RNA-seq.

Understanding Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract, primarily encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD). The global incidence of IBD continues to rise, creating substantial clinical and economic burdens worldwide.

Although both conditions involve intestinal inflammation, they differ significantly in anatomical distribution, immune mechanisms, and pathological progression—factors that critically influence preclinical model selection.

UC vs CD Comparison

Feature	Ulcerative Colitis (UC)	Crohn's Disease (CD)
Distribution Pattern	Continuous inflammation in the colon	Segmental ("skip") lesions throughout the GI tract
Anatomical Location	Limited to the colon	Can affect any part of the GI tract (commonly ileum + colon)
Depth of Inflammation	Mucosal and submucosal layers	Transmural (full-thickness involvement)
Key Pathophysiology	Epithelial barrier disruption, neutrophil infiltration, ulceration	Granuloma formation, fibrosis, strictures, fistula development
Immune Profile	Th2-skewed cytokine response	Th1/Th17-dominant cytokine response
Common Complications	Severe bleeding, toxic megacolon	Strictures, abscesses, perianal disease

The Challenge in IBD Drug Development

Despite advances in biologics targeting TNF-α, integrins, and IL-12/23 pathways, many patients experience incomplete response or disease relapse.

Major challenges include:

Disease heterogeneity
Limited predictive biomarkers
Poor translational consistency between models and clinical outcomes

Given the complexity and heterogeneity of IBD, the choice of preclinical model directly impacts the predictability of therapeutic outcomes. At Creative Bioarray, we offer a comprehensive portfolio of validated IBD models designed to deliver robust, translational, and decision-ready data.

IBD Model Comparison

Model	Advantages	Limitations	Suitable Applications	Clinically Relevant	Mechanism
DSS-induced colitis	Simple, reproducible, rapid	Innate immunity-dominated	Anti-inflammatory drugs, barrier repair agents	Ulcerative Colitis	Epithelial barrier disruption allows luminal antigens to trigger acute inflammation
TNBS-induced colitis	Crohn's-like Th1 response	Technically sensitive, variable	Immunomodulators, biologics	Crohn's Disease	Hapten-induced immune activation drives Th1 cytokine-mediated colitis
Oxazolone-induced colitis	Th2-driven, UC-like	Superficial mucosal damage	Biologics targeting Th2 pathways	Ulcerative Colitis	NKT cell activation induces epithelial damage and Th2 inflammation
IL-10 knockout	Spontaneous chronic colitis	Long modeling time	Mechanistic studies, long-term efficacy	Crohn's Disease	Loss of IL-10 regulation leads to uncontrolled Th1/Th17 immune responses
Adoptive T cell transfer	Chronic immune-driven colitis	Technically demanding	Biologics, immunotherapies	UC & Crohn's Disease	Activated T cells induce sustained intestinal inflammation (Th1/Th17)
Anti-CD40 antibody	Rapid immune activation	Acute inflammation, higher cost	Immune checkpoint modulators	Ulcerative Colitis	CD40-CD40L signaling activates innate immune cells (DCs/macrophages)